Chwee Teck Lim,
NUS Society Chair Professor, Department of Biomedical Engineering, Institute for Health Innovation & Technology (iHealthtech), Mechanobiology Institute,
National University of Singapore
Professor Chwee Teck LIM is the NUS Society Chair Professor of Biomedical Engineering and Director of the Institute for Health Innovation and Technology at the National University of Singapore. His research interest is in the development of microfluidic technologies for applications in disease diagnosis and health monitoring. He has co-authored over 470 journal publications and is also a serial entrepreneur having started six companies. Prof Lim is an Elected Fellow of seven academies including the US National Academy of Inventors, IUPESM, AIMBE, IAMBE, AAET, among others. He and his team have garnered numerous research awards and honours including Asia’s Most Influential Scientist, Highly Cited Researcher, Asian Scientists 100, Wall Street Journal Asian Innovation Award (Gold) and the President's Technology Award among others.
|
|
Microfluidic Enrichment for Single Cancer Cell AnalysisMonday, 20 March 2017 at 16:30 Tumor heterogeneity is currently a major hindrance to cancer diagnosis and treatment. Here, microfluidic technology is used to enrich and enable probing of the molecular heterogeneity of single circulating tumor cells so as to obtain patient derived information for the personalized treatment of cancer patients.
Tumor heterogeneity is a general trait of cancer which has proven to be a major hindrance in cancer classification, diagnosis and treatment. Cancer can be classified loosely into a few distinct sub-types, but recent technological advances have begun to reveal the true extent of its heterogeneity. Single cell analysis is emerging as an important approach to detect variations in morphology or genetic, proteomic and molecular expression. Here, we will present several novel microfluidic technologies to probe the heterogeneity of cancer patient derived circulating tumor cells (CTCs). These include detecting the proteolytic capability of each CTC to obtain hint of their invasiveness as well as identify unique actionable key driver mutations with aim of improving anticancer therapy. It is hope that this single cell analysis approach will not only lead to more precised treatment of cancer patients from the individually derived information of these tumor cells, but will also aid in the development of better drugs to combat this disease.
|
Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com
